[研发][→ 常规进展]Napo Pharmaceuticals（Jaguar Health旗下）赞助阿布扎比儿科胃肠病会议肠道衰竭专题讨论

Jaguar Health旗下Napo Pharmaceuticals赞助10月30日在阿布扎比举行的第2届Best of Elite Ped-GI会议，并赞助题为“Intestinal Barrier Beyond Total Parenteral Nutrition (TPN)”的专题讨论。 公司：Napo Pharmaceuticals 相关资产：crofelemer powder for oral solution 适应症：microvillus inclusion disease (MVID); short bowel syndrome (SBS-IF) 阶段：NDA filing planned mid-2027 融资性质：不适用 来源：BioSpace · 新闻稿（https://www.biospace.com/press-releases/napo-pharmaceuticals-a-jaguar-health-family-company-sponsoring-intestinal-failure-panel-discussion-at-pediatric-gastroenterology-conference-in-abu-dhabi）